Måndag 10 Augusti | 11:59:07 Europe / Stockholm
Est. tid*
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-05 08:00 Kvartalsrapport 2026-Q3
2026-08-13 08:00 Kvartalsrapport 2026-Q2
2026-06-17 - Årsstämma
2026-05-18 - Kvartalsrapport 2026-Q1
2026-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2026-02-12 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-10-27 - Extra Bolagsstämma 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-16 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2025-05-15 - Årsstämma
2025-05-12 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Verksamheten bedrivs främst inom den nordiska marknaden. Bolaget grundades 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Acarix Receives Regulatory Approval for the CADScor®System in the United Arab Emirates

2026-08-10 10:00:00

Approval opens market access across the UAE through commercial partner UniTech Solutions, bringing rapid, non-invasive coronary artery disease rule-out to point of care.

Acarix AB (publ) today announced that the CADScor®System has received regulatory approval from the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP), clearing the way for commercial availability of the technology across the United Arab Emirates.

The approval marks Acarix's entry into the Gulf region and extends the reach of the CADScor System, a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational analysis and AI to assess coronary blood flow and rule out significant coronary artery disease (CAD) in patients presenting with chest pain or shortness of breath. The system delivers a patient-specific result in under 10 minutes, supporting earlier risk stratification and reducing reliance on more invasive and costly downstream testing.

"Coronary artery disease is a leading health burden across the Gulf, and the diagnostic pathway remains longer and more resource-intensive than it needs to be," said Aamir Mahmood, Chief Executive Officer of Acarix. "Bringing the CADScor System to the UAE gives frontline clinicians a fast, non-invasive way to rule out CAD at the point of care. This matters for the patients and clinicians we serve."

The UAE also gives Acarix a platform for the wider Gulf Cooperation Council (GCC), where high case volumes and established clinical infrastructure drive demand for tools that improve triage and ease pressure on cardiac imaging and catheterization labs.

"Entering the UAE is a deliberate step in our strategy to establish the CADScor System as a first-line diagnostic aid in high-value markets," said Beji George, Head of Global Strategy at Acarix. "The market has the infrastructure, the case volume, and the appetite for technology that improves the pathway, and it gives us a strong base to build from across the region."

Acarix will bring the CADScor System to market in the UAE through its commercial partner, UniTech Solutions, which will lead distribution, clinical support, and account development across the region.

"We are proud to bring the CADScor System to healthcare providers across the UAE," said Majed Aboalazm, Chief Executive Officer of UniTech Solutions. "It addresses a clear unmet need, giving clinicians a rapid, reliable way to rule out coronary artery disease early in the pathway. We look forward to working alongside Acarix to put it into the hands of cardiologists and emergency teams."